IL17A and tuberculosis: For IL-17/IL-23/IL-12/23p40 inhibitors, preventive TB therapy was used in 66% of cases "always" or "almost always," 16% case-by-case and 9% "never" or "almost never."<h4>Conclusions</h4>LTBI screening and preventive TB therapy for MTX lack standardization.